AstraZeneca News More News
AstraZeneca Analyst Opinions
- All
- Buy
- Hold
- Sell
AstraZeneca Estimates* in USD
2023 | 2024 | 2025 | 2026 | 2027 | |
---|---|---|---|---|---|
Revenue | 45,915 | 50,388 | 54,138 | 57,769 | 60,373 |
Dividend | 3.05 | 3.16 | 3.31 | 3.43 | 3.69 |
Dividend Yield (in %) | 2.34 % | 2.43 % | 2.54 % | 2.63 % | 2.83 % |
EPS | 7.24 | 8.74 | 9.81 | 10.85 | 11.79 |
P/E Ratio | 18.27 | 15.12 | 13.48 | 12.18 | 11.21 |
EBIT | 14,918 | 17,604 | 19,735 | 21,621 | 23,270 |
EBITDA | 15,832 | 18,636 | 21,015 | 22,290 | 24,898 |
Net Profit | 11,237 | 13,427 | 15,213 | 16,432 | 18,222 |
Net Profit Adjusted | 11,237 | 13,427 | 15,213 | 16,811 | 18,222 |
Pre-Tax Profit | 14,076 | 16,626 | 18,697 | 20,689 | 22,250 |
Net Profit (Adjusted) | 8,500 | 11,224 | 13,483 | 15,512 | 17,806 |
EPS (Non-GAAP) ex. SOE | - | - | - | - | - |
EPS (GAAP) | 4.70 | 5.88 | 7.12 | 8.02 | 9.47 |
Gross Income | 37,601 | 41,254 | 44,992 | 48,097 | 50,577 |
Cash Flow from Investing | -4,097 | -3,860 | -3,967 | -3,876 | -4,648 |
Cash Flow from Operations | 11,652 | 14,022 | 16,255 | 17,465 | 20,852 |
Cash Flow from Financing | -7,361 | -7,827 | -7,386 | -7,525 | -7,820 |
Cash Flow per Share | 7.46 | 8.77 | 9.88 | 9.68 | 12.42 |
Free Cash Flow | 8,292 | 10,645 | 12,553 | 12,591 | 15,299 |
Free Cash Flow per Share | 5.68 | 6.79 | 8.24 | 9.22 | - |
Book Value per Share | 25.40 | 28.64 | 32.86 | 37.63 | 44.80 |
Net Debt | 20,092 | 14,658 | 7,556 | 3,516 | -10,477 |
Research & Development Exp. | 10,133 | 10,784 | 11,346 | 11,975 | 12,043 |
Capital Expenditure | 1,949 | 1,952 | 2,160 | 2,225 | 2,344 |
Selling, General & Admin. Exp. | 14,504 | 14,917 | 15,300 | 15,084 | 15,739 |
Shareholder’s Equity | 39,219 | 43,776 | 49,123 | 55,682 | 67,362 |
Total Assets | 95,834 | 98,574 | 103,969 | 108,101 | 119,691 |
Previous Quarter ending 12/31/22 |
Current Quarter ending 03/31/23 |
Next Quarter ending 06/30/23 |
Current Year ending 12/31/23 |
Next Year ending 12/31/24 |
|
---|---|---|---|---|---|
Earnings Estimates | |||||
No. of Analysts | 19 | 9 | 8 | 29 | 27 |
Average Estimate | 1.343 USD | 1.733 USD | 1.723 USD | 7.237 USD | 8.744 USD |
Year Ago | 1.670 USD | 1.890 USD | 1.720 USD | 6.660 USD | 7.237 USD |
Publish Date | 2/9/2023 | 4/28/2023 | 7/27/2023 | - | - |
Revenue Estimates | |||||
No. of Analysts | 19 | 10 | 9 | 27 | 26 |
Average Estimate | 11,250 USD | 10,790 USD | 11,046 USD | 45,915 USD | 50,388 USD |
Year Ago | 12,011 USD | 11,390 USD | 10,771 USD | 44,351 USD | 45,915 USD |
Publish Date | 2/9/2023 | 4/28/2023 | 7/27/2023 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
AstraZeneca Dividend Calendar
Date | Name | Dividend | *yield | Currency |
---|---|---|---|---|
2022 | AstraZeneca PLC | 2.39 | 2.13 | GBP |
2021 | AstraZeneca PLC | 2.10 | 2.42 | GBP |
2020 | AstraZeneca PLC | 2.07 | 2.83 | GBP |
2019 | AstraZeneca PLC | 2.18 | 2.87 | GBP |
2018 | AstraZeneca PLC | 2.15 | 3.66 | GBP |
2017 | AstraZeneca PLC | 2.02 | 3.95 | GBP |
2016 | AstraZeneca PLC | 2.19 | 4.93 | GBP |
2015 | AstraZeneca PLC | 2.80 | 4.09 | USD |
2015 | AstraZeneca PLC | 1.89 | 4.08 | GBP |
2014 | AstraZeneca PLC | 1.78 | 3.91 | GBP |
2014 | AstraZeneca PLC | 2.80 | 3.95 | USD |
2013 | AstraZeneca PLC | 1.76 | 4.92 | GBP |
2013 | AstraZeneca PLC | 2.80 | 4.75 | USD |
2012 | AstraZeneca PLC | 1.79 | 6.14 | GBP |
2012 | AstraZeneca PLC | 2.80 | 6.08 | USD |
2011 | AstraZeneca PLC | 1.75 | 5.90 | GBP |
2011 | AstraZeneca PLC | 2.80 | 5.95 | USD |
2010 | AstraZeneca PLC | 2.55 | 5.52 | USD |
2010 | AstraZeneca PLC | 1.62 | 5.53 | GBP |
2009 | AstraZeneca PLC | 2.30 | 7.08 | USD |
2009 | AstraZeneca PLC | 1.41 | 4.86 | GBP |
2008 | AstraZeneca PLC | 2.05 | 4.77 | USD |
2007 | AstraZeneca PLC | 1.87 | 5.64 | USD |
2006 | AstraZeneca PLC | 1.72 | 4.09 | USD |
2005 | AstraZeneca PLC | 1.30 | 3.00 | USD |
2004 | AstraZeneca PLC | 0.94 | 3.25 | USD |
2003 | AstraZeneca PLC | 0.80 | 1.95 | USD |
2002 | AstraZeneca PLC | 0.70 | 2.06 | USD |
2001 | AstraZeneca PLC | 0.70 | 1.48 | USD |
2000 | AstraZeneca PLC | 0.70 | 1.35 | USD |
1999 | AstraZeneca PLC | 0.70 | 1.82 | USD |
*Yield of the Respective Date
AstraZeneca PLC Calendar
Event | Estimate | Info | Date |
---|---|---|---|
Annual General Meeting | - | Annual General Meeting | 04/27/2023 |
Earnings Report | 1.733 USD | Q1 2023 Earnings Release | 04/28/2023 |
Earnings Report | 1.723 USD | Q2 2023 Earnings Release | 07/27/2023 |
Earnings Report | - | Q3 2023 Earnings Release | 11/09/2023 |
Earnings Report | - | Q4 2023 Earnings Release | 02/08/2024 |
AstraZeneca PLC Past Events
Event | Actual EPS | Info | Date |
---|---|---|---|
Earnings Report | 1.380 USD | Q4 2022 Earnings Release | 02/09/2023 |
Shareholders' Meeting | - | - | 04/29/2022 |
AstraZeneca Profile
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Moody’s Daily Credit Risk Score
AstraZeneca Shareholder
Owner | in % |
---|---|
Freefloat | 94.95 |
Government Pension Fund - Global (The) | 2.32 |
Vanguard Health Care Fund | 1.28 |
Vanguard Total International Stock Index Fund | 1.26 |
American Funds EuroPacific Growth Fund | 0.78 |
Goldman Sachs GQG Partners International Opportunities Fund | 0.78 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
AstraZeneca Management
Name | Job |
---|---|
Jeffrey Pott | CHRO, Chief Compliance Officer & General Counsel |
Michel Demaré | Chairman-Designate |
Katarina Ageborg | Chief Compliance Officer & EVP-Sustainability |
Cindy L. Hoots | Chief Digital & Information Officer |
Pascal Soriot | Chief Executive Officer & Executive Director |
Aradhana Sarin | Chief Financial Officer & Executive Director |
Marc Pierre Jean Dunoyer | Chief Strategy Officer |
Menelas NICOLAS Pangalos | EVP-Biopharmaceuticals Research & Development |
Tyrell J. Rivers | Executive Director-Corporate Development |
Ruud Dobber | Executive VP-Biopharmaceuticals Business |
Susan Mary Galbraith | Executive VP-Oncology Research & Development |
Pam P. Cheng | Executive VP-Operations & Information Technology |
Iskra Reic | Executive Vice President-Europe & Canada |
David Fredrickson | Executive Vice President-Oncology Business Unit |
Jonathan Thomas Charles Slade | Group Treasurer |
Kevin G. Lokay | Head-U.S. Immuno-oncology |
Nazneen Rahman | Independent Non-Executive Director |
Marcus Wallenberg | Independent Non-Executive Director |
Tony Mok | Independent Non-Executive Director |
Sherilyn D. McCoy | Independent Non-Executive Director |
Deborah DiSanzo | Independent Non-Executive Director |
Ahmed M. Hamdy | Member |
Leif Valdemar Johansson | Non-Executive Chairman |
Diana Layfield | Non-Executive Director |
Andreas Rummelt | Non-Executive Director |
Euan A. Ashley | Non-Executive Director |
Regina Fritsche Danielson | SVP, Head-Research & Early Development |
Adrian Charles Noel Kemp | Secretary |
Sarah Miksinski | Senior Director-Global Regulatory Affairs |
Philip Arthur John Broadley | Senior Independent Non-Executive Director |
Margareta Elisabeth Björk | Senior VP & Head-Late-stage Development |
Helen MacPhee | Vice President |
Sjoerd Hubben | Vice President-Global Government Affairs & Policy |